Why IMU is a multi multi bagger, page-28243

I’ll be honest – I think the IMU thread has become a total Sh$tshow. So instead of engaging I’ve been sending emails to IMU for a response.

Here’s some updates to read on some of the questions ive asked whilst we watch the SP continue to decline.

It has now been over 12 months since the FY23 R&Drebate was due, yet there has been no explanation or update on its delay. GivenImugene’s current financial position, this rebate represents a critical fundingsource, and shareholders deserve clarity on when it will be received.

We acknowledge the delay in the FY23R&D rebate and understand its significance as a funding source for Imugene.The delay has been due to administrative backlog and regulatory process. We areactively working with the ATO to expedite this process and anticipate receivingthe rebate Shareholders will be updated promptly if there are any furtherdevelopments.

Reports indicate Imugene has one quarter of cashremaining, yet we see spending that is difficult to justify. For example,flying five staff members to the United States for the 66th ASH Annual Meetingfeels excessive and indulgent given the company’s financial strain.

Imugene remains focused onoptimizing expenditures to align with our current financial position.Participation in key events like the ASH Annual Meeting is crucial for engagingwith stakeholders, researchers, and potential partners. IMU executives allreside in California to meet with hematology oncologist participants in ourazer-cel trial in the U.S. and Australia already attending the conference.

The decision to pursue trials independently, rather thansecuring partnerships with Big Pharma, has yet to yield results. With nolicensing deals or commercial pathways evident, shareholders are leftquestioning the company’s long-term strategy for value creation. Even with thephase 2 completion of Hervaxx, Imugene have not been able to strike a deal withany BP.

We acknowledge the importance ofsecuring partnerships to create long-term value for shareholders. Whilepursuing independent trials has allowed us to retain full ownership of ourassets, we are actively engaging with Big Pharma and other potential partnersto explore licensing, collaborations, and commercial opportunities. Weremain committed to advancing our pipeline towards commercialization.

Closing statement - Imugene isdedicated to addressing shareholder concerns, improving transparency, anddelivering value through disciplined financial management, clear communication,and focused execution of our clinical and commercial strategy. We will provideregular updates to ensure shareholders remain informed of our progress.